This claim is sourced from a study done by the Case Western Reserve University School of Medicine, which analyzed electronic health records of nearly 1 million people with Type 2 diabetes over three years. The study found that people taking semaglutide (Ozempic) had a 40-70% reduced risk of developing Alzheimer’s compared to those on other antidiabetic medications.
This study has been reported on by a number of varied corroborating sources, including NBC, the University of Texas Health and Science Center, Fox News, and ABC. The article is well-sourced, referencing the study authors directly and acknowledging its limitations, which adds to its credibility.
Overall the claim here is certainly credible but it should be stressed that it is preliminary, as noted by the study's authors. Further clinical trials are necessary to establish this potential benefit conclusively.
